NASDAQ:ZLAB

Zai Lab Stock Forecast, Price & News

$170.90

+6.97 (+4.25 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$164.77

Now: $170.90▼

$171.79

50-Day Range

$106.15

MA: $125.35▼

$163.93

52-Week Range

$43.06

Now: $170.90▼

$171.79

Volume664,533 shs

Average Volume367,420 shs

Market Capitalization$9.93 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.95

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.

MarketRank^™

Overall MarketRank^™

1.22 out of 5 stars

Medical Sector

667th out of 1,480 stocks

Pharmaceutical Preparations Industry

339th out of 612 stocks

1.5 Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $105.67, Zai Lab has a forecasted downside of 38.2% from its current price of $170.90.
Amount of Analyst Coverage
Zai Lab has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Zai Lab has received 190 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zai Lab has received 217 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zai Lab has received 53.32% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote “Outperform” if you believe ZLAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have not sold or bought any company stock.
Percentage Held by Institutions
81.32% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($3.65) to ($3.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -56.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -56.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 33.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZLAB

Previous Symbol

CUSIPN/A

CIK1704292

Webwww.zailaboratory.com

Phone86-21-6163-2588

Employees859

Debt

Debt-to-Equity RatioN/A

Current Ratio8.57

Quick Ratio8.46

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$12.98 million

Price / Sales765.10

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.07 per share

Price / Book33.71

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares58,110,000

Market Cap$9.93 billion

Next Earnings Date3/18/2021 (Estimated)

OptionableOptionable

$170.90

+6.97 (+4.25 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

How has Zai Lab's stock been impacted by Coronavirus?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZLAB stock has increased by 240.9% and is now trading at $170.90.
View which stocks have been most impacted by COVID-19.

Is Zai Lab a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Zai Lab.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Thursday, March, 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.05. The business earned $4.65 million during the quarter.
View Zai Lab's earnings history.

What price target have analysts set for ZLAB?

4 analysts have issued twelve-month target prices for Zai Lab's stock. Their forecasts range from $95.00 to $111.00. On average, they anticipate Zai Lab's share price to reach $105.67 in the next year. This suggests that the stock has a possible downside of 38.2%.
View analysts' price targets for Zai Lab or view Wall Street analyst' top-rated stocks.

Who are some of Zai Lab's key competitors?

Some companies that are related to Zai Lab include Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), Genmab A/S (GMAB), BeiGene (BGNE), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), Shiseido (SSDOY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), UCB (UCBJF), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), Horizon Therapeutics Public (HZNP), CureVac (CVAC) and Ono Pharmaceutical (OPHLF).
View all of ZLAB's competitors.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology Group (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:

Dr. Ying Du, Founder, Chairwoman & CEO (Age 54)
Mr. Tao Fu, Pres, COO & Director (Age 48)
Mr. Ki Chul Cho, Chief Financial Officer (Age 42)
Dr. Harald Reinhart M.D., Chief Medical Officer of Autoimmune & Infectious Diseases (Age 68)
Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 49)
Mr. F. Ty Edmondson, Chief Legal Officer
Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 55)
Dr. Jonathan J. Wang, Sr. VP & Head of Bus. Devel. (Age 38)
Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 56)
Dr. Yunpeng Su M.D., VP & Head of Biologics Discovery - China (Age 45)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include E Fund Management Hong Kong Co. Ltd. (0.03%).

Which institutional investors are buying Zai Lab stock?

ZLAB stock was purchased by a variety of institutional investors in the last quarter, including E Fund Management Hong Kong Co. Ltd..

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $170.90.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $9.93 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 859 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here